


- 185 -


WHAT IS CLAIMED IS:

- 1 1. A compound of Formula (I) or a pharmaceutically acceptable salt, solvate,
 2 stereoisomer or prodrug thereof:



- 3
 4
 5 wherein R^1 is selected from optionally substituted heterocyclylene, optionally substituted
 6 arylene, optionally substituted heteroarylene, optionally substituted aminylacylene,
 7 optionally substituted acylaminylene and optionally substituted acylene;
 8 R^2 is selected from H, halogen and methyl;
 9 R^3 and R^4 are independently selected from H and methyl;
 10 R^5 is selected from H and methyl;
 11 L is an optionally substituted linker having 2 to 18 atoms in the chain length;
 12 X is a protein binding moiety; and
 13 Z is N or CH.

- 1 2. The compound of any preceding claim, having the formula:



- 2
 3 wherein R^6 is H or C_1 - C_6 alkyl, e.g., methyl;
 4 X^1 , X^2 and X^3 are independently selected from N and CH, and $C-L^3$, such that when X^1 and
 5 X^3 are N, X^2 is $C-L^3$; and
 6 L^3 is a linker.


- 1 3. The compound of any preceding claim, wherein X^2 is N; and
 2 X^1 and X^3 are CH.

- 186 -

- 1 4. The compound of any preceding claim, wherein X^2 is N;
 2 X^1 and X^3 are C- L^3 or CH; and
 3 the pyridyl moiety is attached at the 5-position of the oxindole ring.


- 1 5. The compound of any preceding claim, wherein X^2 is N; and
 2 X^1 is C- L^3 .

- 1 6. The compound of any preceding claim, having the formula:



- 2
 3 wherein L^4 is a linker; X^1 , X^2 and X^3 are independently selected from N and CH, and C- L^4 ,
 4 such that when X^1 and X^3 are N, X^2 is C- L^4 .

- 1 7. The compound of any preceding claim, having the formula:




- 2 wherein L^2 is a linker.

1

- 187 -

2 8. The compound of any preceding claim, having the formula:

3




4

5 wherein L¹ is a linker.

1 9. The compound of any preceding claim, wherein X is:


2



3

1 10. The compound of any preceding claim, wherein X is:


2



3

1 11. The compound of any preceding claim, having the formula:

- 188 -




2

3

4 in which L^2 is a linker.


1 12. The compound of any previous claim, having the formula:

2

3 in which L^1 is a linker.

1 13. The compound of any previous claim, having the formula:

2




3

- 189 -

4 in which L^5 is a linker.

1 14. The compound of any preceding claim, having the formula:


2



3 wherein L^5 is a linker.

1 15. The compound of any preceding claim, wherein R^1 is selected from:

2




3

1 16. The compound of any preceding claim, wherein the linker is a member selected from:

2

- 190 -



3

4 wherein the index m is an integer from 1 to 6; and the index n is an integer from 1 to 18.

1 17. The compound of any preceding claim, wherein R^1 is located at either a 5' or 6'
2 position of the oxindole ring.

1 18. The compound of any preceding claim, wherein R¹ is selected from optionally
2 substituted phenylene, optionally substituted pyridinylene, optionally substituted
3 pyrazolylene, optionally substituted aminylacylene, optionally substituted acylaminylene.

1 19. The compound of any preceding claim, wherein the optional substituent at R¹ is
2 selected from optionally substituted heterocyclyl, optionally substituted amino, optionally
3 substituted aminoacyl, optionally substituted acylamino, optionally substituted aryl and
4 optionally substituted heteroaryl.

1 20. The compound of any preceding claim, wherein, R¹ is optionally substituted
2 heteroarylene and R₂ is selected from H, halogen or methyl.

1 21. The compound of any preceding claim, wherein the linker is selected from optionally
2 substituted alkylene, optionally substituted heteroalkylene and optionally substituted
3 cycloalkylene.

22. The compound of any preceding claim, wherein the linker is selected from optionally substituted alkylene, optionally substituted heteroalkylene, optionally substituted cycloalkylene and optionally substituted heterocyclylene, each having 2 to 18 atoms in the


- 191 -

4 chain length, and optionally substituted polyethoxy having 2 to 18 atoms in the chain length.

1 23. The compound of any preceding claim, wherein X is selected from bromodomain-
2 containing protein 4 (BRD4) binding moiety, transcriptional enhanced associate domain
3 (TEAD) binding moiety, Polycomb Repressive Complex 2 (PRC2) binding moiety, focal
4 adhesion kinase (FAK) binding moiety, BCR-ABL binding moiety, Hippo pathway protein
5 binding moiety and transcription factor binding moiety.

1 24. The compound according to any preceding claim, having a formula according to
2 Table 1.

1 25. A compound of Formula (XI) or a pharmaceutically acceptable salt, solvate,
2 stereoisomer or prodrug thereof:





3
4 wherein R^{1'} is selected from optionally substituted heterocyclyl, optionally substituted aryl,
5 optionally substituted heteroaryl, optionally substituted aminoacyl, optionally substituted
6 acylamino and optionally substituted acyl;
7 R² is selected from H, halogen and methyl;
8 R³ and R⁴ are independently selected from H and methyl; and
9 R⁵ is selected from H and methyl; and
10 Z is selected from CH, and N,
11 wherein R^{1'} is located at either a 5' or 6' position of the oxindole ring.

1 26. The compound of Formula (XI) according to 25,
2 wherein R^{1'} is selected from optionally substituted phenyl, optionally substituted pyridinyl,
3 optionally substituted pyrazolyl, optionally substituted indolyl, optionally substituted
4 azaindolyl, optionally substituted aminoacyl, optionally substituted acylamino, optionally
5 substituted heterocyclylacyl and optionally substituted piperidinyl.



1 27. The compound of Formula (XI) according to 25 or 26, as represented by Formula
2 (XI') or (XII''):

- 192 -



3

- 1 28. The compound of Formula (II) according to any one of claims 25-27, as represented
 2 by Formulae (XI'a) or (XI''a):




3

- 4 wherein R², R³, R⁴ and R⁵ are as defined herein, and
 5 wherein R⁶ is selected optionally substituted amino, optionally substituted aminoacyl and
 6 optionally substituted acylamino.

- 1 29. The compound of Formulae (XI'a) or (XI''a) according to any one of claims 25-28,
 2 wherein R⁶ is optionally substituted spirocycloalkyl.

- 1 30. A compound of Formula (XII) or a pharmaceutically acceptable salt, solvate,
 2 stereoisomer or prodrug thereof:



3

- 4 wherein R₁, R₂, R₃, R₄ and R₅ are as defined herein;

- 193 -

- 5 wherein R₁ is located at either a 5' or 6' position of the oxindole ring; and
6 L is an optionally substituted linker having 2 to 18 atoms in the chain length.

1 31. A pharmaceutical composition comprising an effective amount of compound of a
2 compound of any preceding claim or a pharmaceutically acceptable salt, solvate,
3 stereoisomer or prodrug thereof, optionally in combination with a pharmaceutically
4 acceptable carrier, excipient or diluent.

1 32. A method of inducing degradation of an overexpressed protein in a cell, including a
2 step of contacting a compound of any preceding claim with the cell to induce degradation of
3 the overexpressed protein in the cell.

1 33. A method of treating a disease or condition associated with an overexpressed protein,
2 comprising administering a compound of any preceding claim or a pharmaceutically
3 acceptable salt, solvate, stereoisomer or prodrug thereof in a patient in need thereof.

1 34. The method according to either of claims 32 or 33, wherein the overexpressed protein
2 is selected from BRD4, transcriptional enhanced associate domain (TEAD), Polycomb
3 Repressive Complex 2 (PRC2), focal adhesion kinase (FAK), BCR-ABL, Hippo pathway
4 protein and transcription factor.

1 35. The method according to any one of claims 32-34, wherein the disease or condition
2 is selected from hyperplasia and cancer (such as multiple myeloma, glioblastoma, uveal
3 melanoma, liposarcoma, hepatocellular carcinoma, midline carcinoma, acute myeloid
4 leukemia, Burkitt lymphoma and prostate cancer) and a protein accumulation disease (such
5 as Alzheimer's disease and amyotrophic lateral sclerosis).

1 36. A compound of any of claims 1-30 or a pharmaceutically acceptable salt, solvate,
2 stereoisomer or prodrug thereof for use as a medicament.

1 37. A compound of any of claims 1-30 or a pharmaceutically acceptable salt, solvate,
2 stereoisomer or prodrug thereof for use in the treatment of a disease or condition associated
3 with an overexpressed protein.

1 38. The compound according to either of claims 36 or 37, wherein the disease or

- 194 -

2 condition is selected from hyperplasia and cancer (such as multiple myeloma, glioblastoma,
3 uveal melanoma, liposarcoma, hepatocellular carcinoma, midline carcinoma, acute myeloid
4 leukemia, Burkitt lymphoma and prostate cancer) and a protein accumulation disease (such
5 as Alzheimer's disease and amyotrophic lateral sclerosis).

1 39. Use of a compound of any of claims 1-30 or a pharmaceutically acceptable salt,
2 solvate, stereoisomer or prodrug thereof in the manufacture of a medicament for the
3 treatment of a disease or condition associated with an overexpressed protein.

1 40. The use according to claim 39, wherein the disease or condition is selected from
2 hyperplasia, cancer (such as multiple myeloma, glioblastoma, uveal melanoma,
3 liposarcoma, hepatocellular carcinoma, midline carcinoma, acute myeloid leukemia, Burkitt
4 lymphoma and prostate cancer) and protein-accumulation disease (such as Alzheimer's
5 disease and amyotrophic lateral sclerosis).

1 41. A ternary complex comprising a first protein and a second protein interacting with
2 a first moiety and a second moiety, respectively, of the compound of any of claims 1-24.